93 related articles for article (PubMed ID: 25451255)
1. The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway.
Takamiya R; Takahashi M; Uehara Y; Ariki S; Hashimoto J; Hasegawa Y; Kuroki Y
Biochem Biophys Res Commun; 2014 Nov; 454(3):364-8. PubMed ID: 25451255
[TBL] [Abstract][Full Text] [Related]
2. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.
Takahashi M; Hasegawa Y; Ikeda Y; Wada Y; Tajiri M; Ariki S; Takamiya R; Nishitani C; Araki M; Yamaguchi Y; Taniguchi N; Kuroki Y
J Biol Chem; 2013 Nov; 288(46):32910-21. PubMed ID: 24097984
[TBL] [Abstract][Full Text] [Related]
3. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
4. Heregulin/ErbB3 Signaling Enhances CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1α.
Lopez-Haber C; Barrio-Real L; Casado-Medrano V; Kazanietz MG
Mol Cell Biol; 2016 Aug; 36(15):2011-26. PubMed ID: 27185877
[TBL] [Abstract][Full Text] [Related]
5. HRG-β1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells.
Kim J; Jeong H; Lee Y; Kim C; Kim H; Kim A
BMC Cancer; 2013 Aug; 13():383. PubMed ID: 23937725
[TBL] [Abstract][Full Text] [Related]
6. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
Hutcheson IR; Goddard L; Barrow D; McClelland RA; Francies HE; Knowlden JM; Nicholson RI; Gee JM
Breast Cancer Res; 2011 Mar; 13(2):R29. PubMed ID: 21396094
[TBL] [Abstract][Full Text] [Related]
7. The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion.
Yokoe S; Takahashi M; Asahi M; Lee SH; Li W; Osumi D; Miyoshi E; Taniguchi N
Cancer Res; 2007 Mar; 67(5):1935-42. PubMed ID: 17332320
[TBL] [Abstract][Full Text] [Related]
8. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Laughner E; Taghavi P; Chiles K; Mahon PC; Semenza GL
Mol Cell Biol; 2001 Jun; 21(12):3995-4004. PubMed ID: 11359907
[TBL] [Abstract][Full Text] [Related]
9. Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells.
Lee S; Hallis SP; Jung KA; Ryu D; Kwak MK
Redox Biol; 2019 Jun; 24():101210. PubMed ID: 31078780
[TBL] [Abstract][Full Text] [Related]
10. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
[TBL] [Abstract][Full Text] [Related]
11. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Ostrander JH; Daniel AR; Lofgren K; Kleer CG; Lange CA
Cancer Res; 2007 May; 67(9):4199-209. PubMed ID: 17483331
[TBL] [Abstract][Full Text] [Related]
12. Suppression of tumor angiogenesis by metformin treatment via a mechanism linked to targeting of HER2/HIF-1α/VEGF secretion axis.
Wang J; Li G; Wang Y; Tang S; Sun X; Feng X; Li Y; Bao G; Li P; Mao X; Wang M; Liu P
Oncotarget; 2015 Dec; 6(42):44579-92. PubMed ID: 26625311
[TBL] [Abstract][Full Text] [Related]
13. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
[TBL] [Abstract][Full Text] [Related]
14. Nrf2 promotes breast cancer cell migration via up-regulation of G6PD/HIF-1α/Notch1 axis.
Zhang HS; Zhang ZG; Du GY; Sun HL; Liu HY; Zhou Z; Gou XM; Wu XH; Yu XY; Huang YH
J Cell Mol Med; 2019 May; 23(5):3451-3463. PubMed ID: 30809937
[TBL] [Abstract][Full Text] [Related]
15. Heregulin-β1-induced GPR30 upregulation promotes the migration and invasion potential of SkBr3 breast cancer cells via ErbB2/ErbB3-MAPK/ERK pathway.
Ruan SQ; Wang ZH; Wang SW; Fu ZX; Xu KL; Li DB; Zhang SZ
Biochem Biophys Res Commun; 2012 Apr; 420(2):385-90. PubMed ID: 22425775
[TBL] [Abstract][Full Text] [Related]
16. Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.
Momeny M; Saunus JM; Marturana F; McCart Reed AE; Black D; Sala G; Iacobelli S; Holland JD; Yu D; Da Silva L; Simpson PT; Khanna KK; Chenevix-Trench G; Lakhani SR
Oncotarget; 2015 Feb; 6(6):3932-46. PubMed ID: 25668816
[TBL] [Abstract][Full Text] [Related]
17. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
18. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Yang C; Liu Y; Lemmon MA; Kazanietz MG
Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-β1-induced breast cancer cell aggressiveness through downregulating HIF-1α expression.
Cho KH; Yu SL; Cho DY; Park CG; Lee HY
BMC Cancer; 2015 Oct; 15():829. PubMed ID: 26520789
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
